Citadel Advisors’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.6M | Buy |
248,300
+179,300
| +260% | +$14.2M | ﹤0.01% | 2411 |
|
|
2025
Q4 | $5.46M | Sell |
69,000
-7,100
| -9% | -$535K | ﹤0.01% | 4157 |
|
|
2025
Q3 | $4.98M | Buy |
76,100
+18,900
| +33% | +$923K | ﹤0.01% | 4375 |
|
|
2025
Q2 | $2.26M | Sell |
57,200
-700
| -1% | -$22.9K | ﹤0.01% | 5476 |
|
|
2025
Q1 | $1.75M | Sell |
57,900
-2,200
| -4% | -$72K | ﹤0.01% | 5795 |
|
|
2024
Q4 | $2.1M | Buy |
60,100
+20,500
| +52% | +$766K | ﹤0.01% | 5513 |
|
|
2024
Q3 | $1.59M | Sell |
39,600
-15,600
| -28% | -$726K | ﹤0.01% | 5943 |
|
|
2024
Q2 | $2.63M | Buy |
55,200
+17,200
| +45% | +$705K | ﹤0.01% | 4811 |
|
|
2024
Q1 | $1.65M | Buy |
38,000
+18,200
| +92% | +$868K | ﹤0.01% | 5900 |
|
|
2023
Q4 | $1M | Buy |
19,800
+11,800
| +148% | +$565K | ﹤0.01% | 6676 |
|
|
2023
Q3 | $363K | Sell |
8,000
-9,500
| -54% | -$392K | ﹤0.01% | 8761 |
|
|
2023
Q2 | $718K | Sell |
17,500
-21,200
| -55% | -$815K | ﹤0.01% | 7138 |
|
|
2023
Q1 | $1.38M | Buy |
38,700
+15,500
| +67% | +$582K | ﹤0.01% | 6075 |
|
|
2022
Q4 | $876K | Buy |
23,200
+2,200
| +10% | +$92.5K | ﹤0.01% | 7059 |
|
|
2022
Q3 | $929K | Buy |
21,000
+1,200
| +6% | +$50.6K | ﹤0.01% | 7157 |
|
|
2022
Q2 | $733K | Sell |
19,800
-6,600
| -25% | -$249K | ﹤0.01% | 7750 |
|
|
2022
Q1 | $978K | Sell |
26,400
-15,400
| -37% | -$504K | ﹤0.01% | 7740 |
|
|
2021
Q4 | $1.27M | Sell |
41,800
-5,000
| -11% | -$157K | ﹤0.01% | 7314 |
|
|
2021
Q3 | $1.57M | Sell |
46,800
-28,500
| -38% | -$1.07M | ﹤0.01% | 6973 |
|
|
2021
Q2 | $3M | Sell |
75,300
-10,100
| -12% | -$396K | ﹤0.01% | 5600 |
|
|
2021
Q1 | $3.84M | Buy |
85,400
+43,100
| +102% | +$2.4M | ﹤0.01% | 4866 |
|
|
2020
Q4 | $2.39M | Buy |
42,300
+20,000
| +90% | +$997K | ﹤0.01% | 4983 |
|
|
2020
Q3 | $1.06M | Buy |
22,300
+5,600
| +34% | +$311K | ﹤0.01% | 5939 |
|
|
2020
Q2 | $985K | Sell |
16,700
-23,600
| -59% | -$1.31M | ﹤0.01% | 5854 |
|
|
2020
Q1 | $1.91M | Sell |
40,300
-30,900
| -43% | -$1.72M | ﹤0.01% | 4216 |
|
|
2019
Q4 | $4.3M | Buy |
71,200
+1,500
| +2% | +$89.4K | ﹤0.01% | 3264 |
|
|
2019
Q3 | $4.18M | Sell |
69,700
-14,200
| -17% | -$925K | ﹤0.01% | 3355 |
|
|
2019
Q2 | $5.39M | Sell |
83,900
-7,800
| -9% | -$551K | ﹤0.01% | 2986 |
|
|
2019
Q1 | $7.44M | Buy |
91,700
+6,600
| +8% | +$426K | ﹤0.01% | 2431 |
|
|
2018
Q4 | $4.6M | Sell |
85,100
-90,500
| -52% | -$4.62M | ﹤0.01% | 2903 |
|
|
2018
Q3 | $9.06M | Buy |
175,600
+86,500
| +97% | +$4.06M | ﹤0.01% | 2227 |
|
|
2018
Q2 | $3.71M | Buy |
89,100
+8,200
| +10% | +$363K | ﹤0.01% | 3177 |
|
|
2018
Q1 | $3.57M | Sell |
80,900
-9,400
| -10% | -$478K | ﹤0.01% | 2887 |
|
|
2017
Q4 | $4.54M | Buy |
90,300
+15,400
| +21% | +$844K | ﹤0.01% | 2582 |
|
|
2017
Q3 | $3.8M | Buy |
74,900
+24,600
| +49% | +$1.29M | ﹤0.01% | 2616 |
|
|
2017
Q2 | $2.56M | Sell |
50,300
-10,000
| -17% | -$466K | ﹤0.01% | 2853 |
|
|
2017
Q1 | $2.42M | Sell |
60,300
-10,000
| -14% | -$449K | ﹤0.01% | 2844 |
|
|
2016
Q4 | $3.36M | Sell |
70,300
-9,200
| -12% | -$364K | ﹤0.01% | 2386 |
|
|
2016
Q3 | $2.91M | Sell |
79,500
-1,600
| -2% | -$50.1K | ﹤0.01% | 2532 |
|
|
2016
Q2 | $1.89M | Buy |
81,100
+26,200
| +48% | +$845K | ﹤0.01% | 2815 |
|
|
2016
Q1 | $2.22M | Buy |
+54,900
| New | +$2.23M | ﹤0.01% | 2536 |
|
|
2015
Q4 | – | Sell |
-42,900
| Closed | -$1.73M | – | 8926 |
|
|
2015
Q3 | $1.73M | Sell |
42,900
-65,800
| -61% | -$3.41M | ﹤0.01% | 3128 |
|
|
2015
Q2 | $6.26M | Sell |
108,700
-14,100
| -11% | -$897K | 0.01% | 1860 |
|
|
2015
Q1 | $7.82M | Buy |
122,800
+60,400
| +97% | +$4.1M | 0.01% | 1637 |
|
|
2014
Q4 | $3.85M | Buy |
62,400
+14,400
| +30% | +$711K | ﹤0.01% | 2228 |
|
|
2014
Q3 | $1.86M | Buy |
48,000
+12,000
| +33% | +$425K | ﹤0.01% | 2920 |
|
|
2014
Q2 | $1.24M | Sell |
36,000
-14,400
| -29% | -$453K | ﹤0.01% | 3224 |
|
|
2014
Q1 | $2.18M | Buy |
50,400
+13,000
| +35% | +$630K | ﹤0.01% | 2569 |
|
|
2013
Q4 | $1.49M | Sell |
37,400
-63,300
| -63% | -$2.26M | ﹤0.01% | 2824 |
|
|
2013
Q3 | $3.78M | Buy |
100,700
+61,100
| +154% | +$1.83M | 0.01% | 1811 |
|
|
2013
Q2 | $1.06M | Buy |
+39,600
| New | +$842K | ﹤0.01% | 3132 |
|
Other funds holding IONS
VPM
VCM
Citadel Advisors's IONS Position: Q1 2026 in Review
Citadel Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 56% in Q1 2026, selling an estimated $94.1M and leaving 942,534 shares worth $70.8M. The position accounts for 0.01% of the portfolio, ranked #1072.
Citadel Advisors first reported a position in IONS in Q2 2013 and has held it in 47 quarters since. The position peaked at $169M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Citadel Advisors held 942,534 shares of Ionis Pharmaceuticals worth $70.8M as of Q1 2026.
- Citadel Advisors sold 1,192,102 Ionis Pharmaceuticals shares in Q1 2026, an estimated $94.1M.
- Ionis Pharmaceuticals made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1072 holding.
- Citadel Advisors first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
- Citadel Advisors's Ionis Pharmaceuticals position peaked at $169M in Q4 2025.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.